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Background:  Resting heart rate (HR), as it increases, is a modifiable risk factor for adverse outcomes in chronic systolic heart failure 
(CHF). Ivabradine reduces HR by selectively inhibiting the f-current (If) in the sinus node. In the Systolic Heart failure treatment with the If 
inhibitor ivabradine Trial (SHIFT), lowering HR with ivabradine in patients with CHF (LV ejection fraction [EF] ≤ 35%) significantly reduced 
cardiovascular (CV) death and hospitalization for worsening HF (WHF). The SIGNIFY trial showed that lowering heart rate did not reduce 
CV death or nonfatal myocardial infarction (MI) in patients with coronary artery disease without LV dysfunction or clinical HF and slightly 
increased these events in the subgroup with angina. To assess the efficacy of ivabradine in CHF patients who have angina (ANG), we 
analyzed data for this subgroup from the SHIFT study.
methods:  Of the 6505 evaluable patients from SHIFT, 68% had ischemic etiology; 2220 (34%) had a history of ANG at baseline. We 
assessed the effect of ivabradine on the occurrence of CV death or hospitalization for WHF, and on CV death or nonfatal MI, both in the full 
SHIFT randomized set (RS) and in the ANG subgroup.
results:  Ivabradine reduced CV death or hospitalization for WHF by 18% compared with placebo in the RS (hazard ratio [HR] = 0.82; 95% 
confidence interval [CI] = 0.75, 0.90; p < 0.0001), and by 15% in the ANG subgroup (HR = 0.85; 95% CI = 0.73, 1.00; p = 0.0553). Effects 
of ivabradine on components of CV death and hospitalization for WHF were similar between RS and ANG. Ivabradine reduced CV death or 
nonfatal MI by 11% versus placebo in the RS (HR = 0.89; 95% CI = 0.79, 1.01; p = 0.0660), and by 8% (HR = 0.92; 95% CI = 0.75, 1.12; p 
= 0.3797) in the ANG subgroup. Both groups showed directionally consistent results for nonfatal MI, HR = 0.93 (95% CI = 0.67, 1.30) and 
HR = 0.86 (95% CI = 0.53, 1.40) in the RS and ANG subgroups, respectively.
conclusion:  Ivabradine showed a consistent reduction of CV death or hospitalization for WHF in SHIFT patients with CHF and angina, as 
also observed for all SHIFT patients, with no increase in the risk of nonfatal MI.
